EIGRQ — Eiger Biopharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $12.59m
- $28.27m
- $15.77m
- 37
- 38
- 94
- 56
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.8 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | -367% | ||
| Operating Margin | -455.12% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 12.14 | 13.48 | 15.77 | 25.22 | 32.65 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. Its HDV platform includes lonafarnib, an oral farnesylation inhibitor that targets a critical host process involved in viral replication. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV, Combination Therapy for HDV, and Peginterferon Lambda (lambda) for COVID-19. LNF is an orally bioavailable, farnesylation inhibitor that has completed a Phase 3 clinical trial for HDV infection. LNF has demonstrated dose-dependent activity in reducing HDV viral load both as a monotherapy and in combination with ritonavir (RTV) and/or PEG IFN-alfa-2a. Lambda is a type III, well-tolerated interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections.
Directors
- Thomas Dietz NEC (57)
- David Cory PRE (57)
- Sriram Ryali CFO (40)
- Eldon Mayer EVP (59)
- Erik Atkisson CCO
- James Shaffer OTH (54)
- David Apelian DRC (56)
- Jeffrey Glenn IND (58)
- Evan Loh IND (62)
- Christine Murray IND (60)
- Kim Sablich IND (52)
- Amit Sachdev IND (63)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 24th, 2012
- Public Since
- January 30th, 2014
- No. of Shareholders
- 17
- No. of Employees
- 25
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 1,480,797
- Address
- 2155 Park Blvd, PALO ALTO, 94306-1543
- Web
- https://www.eigerbio.com/
- Phone
- +1 6502799845
- Auditors
- KPMG LLP
Upcoming Events for EIGRQ
Q3 2024 Eiger BioPharmaceuticals Inc Earnings Release
Similar to EIGRQ
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
What is the Eiger Biopharmaceuticals share price?
As of Today at 20:24 UTC, shares in Eiger Biopharmaceuticals are trading at $8.50. This share price information is delayed by 15 minutes.
How has the Eiger Biopharmaceuticals share price performed this year?
Shares in Eiger Biopharmaceuticals last closed at $8.50 and the price had moved by -6.18% over the past 365 days. In terms of relative price strength the Eiger Biopharmaceuticals share price has underperformed the S&P500 Index by -27.05% over the past year.
What are the analyst and broker recommendations for Eiger Biopharmaceuticals?
The overall consensus recommendation for Eiger Biopharmaceuticals is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Eiger Biopharmaceuticals dividend yield?
Eiger Biopharmaceuticals does not currently pay a dividend.
Does Eiger Biopharmaceuticals pay a dividend?
Eiger Biopharmaceuticals does not currently pay a dividend.
When does Eiger Biopharmaceuticals next pay dividends?
Eiger Biopharmaceuticals does not currently pay a dividend.
How do I buy Eiger Biopharmaceuticals shares?
To buy shares in Eiger Biopharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Eiger Biopharmaceuticals?
As of the previous close price of $8.50, shares in Eiger Biopharmaceuticals had a market capitalisation of $12.59m.
Where are Eiger Biopharmaceuticals shares listed?
Here are the trading details for Eiger Biopharmaceuticals:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: EIGRQ
What kind of share is Eiger Biopharmaceuticals?
Based on an overall assessment of its quality, value and momentum Eiger Biopharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Eiger Biopharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in Eiger Biopharmaceuticals is $30.00. That is 252.94% above the last closing price of $8.50.
Analysts covering Eiger Biopharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$15.60 for the next financial year.
Find out moreWhat is the trend in the Eiger Biopharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Eiger Biopharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +56.35%.
As of the last closing price of $8.50, shares in Eiger Biopharmaceuticals were trading +22.29% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Eiger Biopharmaceuticals PE Ratio?
The Eiger Biopharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $8.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Eiger Biopharmaceuticals?
Eiger Biopharmaceuticals' management team is headed by:
- Thomas Dietz - NEC
- David Cory - PRE
- Sriram Ryali - CFO
- Eldon Mayer - EVP
- Erik Atkisson - CCO
- James Shaffer - OTH
- David Apelian - DRC
- Jeffrey Glenn - IND
- Evan Loh - IND
- Christine Murray - IND
- Kim Sablich - IND
- Amit Sachdev - IND